Last reviewed · How we verify
NCT04786522: IRICDE
Irisin Levels in Patients With Charcot-Marie-Tooth (CMT) Disease
trial testing Bioimpedenziometry, Handgrip strenght evaluation in Charcot-Marie-Tooth Disease in 20 participants. Completed in 30 December 2020.
31 October 2020
Quick facts
| Lead sponsor | University of Bari |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 20 |
| Start date | 2 November 2019 |
| Primary completion | 31 October 2020 |
| Estimated completion | 30 December 2020 |
| Sites | 1 location across Italy |
Drugs / interventions tested
- Bioimpedenziometry, Handgrip strenght evaluation
- Evaluation on blood specimens
Conditions studied
- Charcot-Marie-Tooth Disease — all drugs for Charcot-Marie-Tooth Disease →
Sponsor
University of Bari
Who can join
Eligibility, any sex, with Charcot-Marie-Tooth Disease. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Irisin is an exercise-mimetic myokine secreted by skeletal muscle. Compelling evidence in animal models and humans showed that Irisin prevents onset of musculoskeletal atrophy and its low serum levels are predictive of sarcopenia. The investigators evaluated the levels of irisin in patients affected by an hereditary motor and sensory neuropathy, namely Charcot-Marie-Tooth disease (CMT), in order to investigate possible key determinants of their muscle quality and possibly prevent the progressive distal weakness and muscle atrophy.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Irisin Serum Levels and Skeletal Muscle Assessment in a Cohort of Charcot-Marie-Tooth Patients.
Colaianni G, Oranger A, Dicarlo M, Lovero R, et al · · 2022 · cited 19× · PMID 35634506 · DOI 10.3389/fendo.2022.886243
Verify or expand the search:
- PubMed search for NCT04786522
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Charcot-Marie-Tooth Disease
Currently open trials in the same condition.
- NCT06203093 — Charcot-Marie-Tooth Disease (CMT) Biological Sample Collection for IPSC Generation and Biobanking · recruiting
- NCT04762758 — Phase III Trial Assessing the Efficacy and Safety of PXT3003 in CMT1A Patients · Phase 3 · active not recruiting
- NCT04010188 — A Registered Cohort Study on Charcot-Marie-Tooth Disease · recruiting
- NCT05902351 — Natural History Study for Charcot Marie Tooth Disease · recruiting
Other University of Bari trials
Trials by the same sponsor.
- NCT06854133 — Factors of Effectiveness in Italian Forensic Treatment · not yet recruiting
- NCT07125625 — Probiotic Mixture (L. Rhamnosus GG and L. Plantarum 299V) In Pediatric Irritable Bowel Syndrome · NA · not yet recruiting
- NCT07036627 — Intestinal Microbiota After PPI Treatment · not yet recruiting
- NCT07050693 — Efficacy of a 2'-Fucosylactose-based Food Supplement on the Prevention of Respiratory and Gastrointestinal Infections. · NA · recruiting
- NCT06719999 — PRIMA Project- Box for Heath and Tradition (B4HT) · NA · active not recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04786522 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University of Bari
- Last refreshed: 10 March 2021
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04786522.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing